ALPL
EstablishedALPL encodes an enzyme whose reduced levels indicate tumor aggressiveness in breast cancer, and whose mutations cause a distinct genetic bone disease.
ALPL is the gene for an enzyme important in bone and liver health. Low levels in breast cancer tissue may signal more aggressive disease. Separately, ALPL mutations cause a rare inherited bone disease called hypophosphatasia — a completely different condition from the cancer context.
ALPL encodes tissue-nonspecific alkaline phosphatase, active in bone, liver, and kidney, and important for bone mineralization. In oncology, altered ALPL/alkaline phosphatase expression has been studied as a marker of tumor aggressiveness, particularly in breast cancer.
Lower serum or tissue ALPL/alkaline phosphatase in breast cancer correlates with more aggressive disease, higher stage, and increased risk of bone metastasis. Separately, and clinically more established, loss-of-function ALPL mutations cause hypophosphatasia, a genetic bone-mineralization disorder unrelated to cancer.
Measured via standard serum ALP assays with isoenzyme differentiation to distinguish bone from liver source; genetic testing of the ALPL gene confirms hypophosphatasia when clinically suspected (low ALP with skeletal abnormalities).
No direct ALPL-targeted cancer therapies are approved; in hypophosphatasia, enzyme replacement therapy (asfotase alfa) is available and guided by genetic/biochemical diagnosis.
Reduced ALPL is linked to cancer progression and metastasis; also the causal gene in hypophosphatasia.
- Jiang, C., Hu, F., Xia, X., & Guo, X. (2023). Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer. International Journal of Biological Markers.
- StatPearls. (2023). Hypophosphatasia.